ArticleBMC nephrology2026
Triglyceride-glucose index and the outcome of peritoneal dialysis patients: analysis of two cohorts.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease is the leading cause of death in patients with chronic kidney disease and those on peritoneal dialysis (PD), with insulin resistance contributing significantly to adverse outcomes. This study evaluates the triglyceride-glucose (TyG) index as a prognostic marker for metabolic dysfunction in PD patients.
methodsWe studied two patient cohorts: 278 new PD patients and 178 prevalent ones. TyG index values were calculated by a validated formula. The patients were followed for 28.0 ± 12.6 (incident PD cohort) and 43.9 ± 37.6 months (prevalent PD cohort) for survival and hospitalization.
resultsThe mean TyG index was 8.70 ± 0.61 and 9.01 ± 0.72 in the new and prevalent PD cohort, respectively (p < 0.0001). In the incident PD cohort, the 2-year patient survival rates for quartiles I to IV of TyG were 84.0%, 85.9%, 79.8%, and 73.8%, respectively (p = 0.045). However, after adjustment for confounders, TyG was not an independent predictor of patient survival (adjusted hazard ratio 0.958, 95% confidence interval 0.732 to 1.123, p = 0.753). In the prevalent PD cohort, the 2-year patient survival rates for quartiles I to IV of TyG were 68.9%, 75.0%, 84.4%, and 75.0%, respectively (p = 0.364). In both cohorts, TyG index showed no significant association with technique survival rate, hospitalization rates, duration of hospitalization, or peritonitis rates.
conclusionsThe TyG index was higher in prevalent PD patients but was not an independent predictor of patient or technique survival, hospitalization, or peritonitis rate after multivariate adjustment. Although correlated with metabolic parameters, the TyG index did not serve as a prognostic marker in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.